Herbas VPB

Print
EN | LT
LT - Dasatinibo ir adagrasibo derinys, skirtas panaudoti nesmulkialąstelinio plaučių vėžio gydymui
EN - COMBINATION OF DASATINIB AND ADAGRASIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER

Legal status

Patent in force

Bibliographic data
Indications of the International Patent Classification (IPC)
(51) INT.CL. A61K 31/5025 (2006.01)
A61K 31/506 (2006.01)
A61K 31/517 (2006.01)
A61K 31/519 (2006.01)
A61K 31/5377 (2006.01)
A61K 31/541 (2006.01)
A61K 31/553 (2006.01)
A61K 45/06 (2006.01)
A61P 35/00 (2006.01)
A61P 35/02 (2006.01)
A61K 9/00 (2006.01)
European patent
(11) Number of the document 3849534
(13) Kind of document T
(96) European patent application number 19858883.2
Date of filing the European patent application 2019-09-09
(97) Date of publication of the European application 2021-07-21
(45) Date of publication and mention of the grant of the patent 2025-03-05
(46) Date of publication of the claims translation 2025-05-12
PCT application
(86) Number PCT/US2019/050224
Date 2019-09-09
PCT application publication
(87) Number WO 2020/055755
Date 2020-03-19
Priority applications
(30) Number Date Country code
201862729169 P 2018-09-10 US
Inventors
(72)
ENGSTROM, Lars, Daniel , US
ARANDA, Ruth, Wei , US
OLSON, Peter , US
CHRISTENSEN, James, Gail , US
Grantee
(73) Mirati Therapeutics, Inc. , Route 206 and Province Line Road, Princeton, New Jersey 08543, US
Attorney or representative
(74) Otilija KLIMAITIENĖ, AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius, LT
Title
(54) Dasatinibo ir adagrasibo derinys, skirtas panaudoti nesmulkialąstelinio plaučių vėžio gydymui
  COMBINATION OF DASATINIB AND ADAGRASIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
Last renewal fee
Payment date Validity (years) Amount
2025-08-04 7 162.00 EUR
Next renewal fee
2026-09-09